DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for epilepsia partialis continua — screening already-approved drugs against its 14-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleEpilepsia partialis continua maps to a 14-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for epilepsia partialis continua is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
gamma-aminobutyric acid type A receptor subunit alpha4 (GABRA4) — GABRA4 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet px6drag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 7QN5 · 2.5 Å · ligand 1,2-DIPALMITOYL-SN-GLYCERO-3-PHOSPHATE (PX6). Experimental structure, not a prediction.
What the evidence adds up to
Eight patients with Rasmussen's syndrome and epilepsia partialis continua received high doses of steroids, including methylprednisolone pulses and tapering prednisone. Three had bilateral involvement. Epilepsy and focal deficit decreased within six months in seven patients. A lasting effect occurred only in the five patients who began steroid treatment less than 15 months after onset, though they still had periodic transient relapses. The authors advise high-dose steroids during the first year after onset, before hemiplegia develops, and in bilateral cases.
A 64-year-old woman with no neurologic history presented with 18 months of epilepsia partialis continua, moderate intellectual deterioration, and subtle extrapyramidal rigidity. Rectal mucosa biopsy showed fingerprint profiles diagnostic of Kufs' disease. The authors note that adult-onset epilepsia partialis continua should prompt consideration of this diagnosis.
Two children with onset of epilepsia partialis continua at age 8 were studied with EEG and cranial computed tomography. The CT showed the underlying morphological lesion, while the EEG showed the epileptic phenomena. The anatomical lesion and the EEG focus could have quite different localisations. The authors state that CT proof of a cortical and subcortical lesion seems important for establishing the diagnosis.
What is still missing: prospective trials of steroid timing and dosing in Rasmussen's syndrome, systematic screening for Kufs' disease in adult-onset epilepsia partialis continua, and modern imaging studies that correlate lesion location with EEG findings in larger patient cohorts.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Neurology Neurosurgery & Psychiatry · 1994 · 90 citations · open access
Reappraisal of Rasmussen's syndrome with special emphasis on treatment with high doses of steroids.
AbstractEight patients with Rasmussen's syndrome and epilepsia partialis continua were treated with high doses of steroids, including pulses of methylprednisolone and prednisone in decreasing doses. Three patients exhibited clinical, radiological, or histological evidence of bilateral involvement. Epilepsy and focal deficit decreased within six months in seven patients. Only five patients, in whom steroid treatment had begun less than 15 months after the onset of epilepsia partialis continua, experienced a lasting effect although they had periodic episodes of transient relapse. Treatment with high doses of steroids seems advisable during the first year after onset of epilepsia partialis continua, before hemiplegia has developed and in cases with bilateral involvement.
Kufs' disease presenting as late-onset epilepsia partialis continua
AbstractA 64-year-old woman, who had no personal or family history of neurologic diseases, had an 18-month history of epilepsia partialis continua (EPC) associated with a moderate intellectual deterioration and subtle extrapyramidal rigidity. There was no photosensitive response. A thorough laboratory investigation was unremarkable. A biopsy of the rectal mucosa revealed abundant fingerprint profiles diagnostic of Kufs' disease (KD). Our case expands the clinical picture of KD and suggests that such a diagnosis should be considered in adult-onset EPC.
Epilepsia partialis continua KozevnikovKorrelation von Computertomogramm und EEG-Befund*
AbstractTwo children with onset of epilepsia partialis continua (Epc) in the age of 8 years are described. EEG-findings and cranial computertomography are compared. Where as the CAT is demonstrating the underlying morphological lesion of Epc, the EEG is showing the epileptic phenomena. Both, anatomic lesion and electroencephalographic focus can show quite different localisations. Despite this findings, to establish the diagnosis Epc, in our cases the computertomographic proof of a cortical and subcortical lesion seems to be important.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
